Key facts
- Tasca Therapeutics’s last known valuation is $83.3M (Sep 2025).
- It has raised $67.0M across 1 recorded rounds; the latest was Early Stage VC ($48.1M) in Nov 2024.
- Notable investors include 8VC, The Invus Group, TIFF Investment Management, AB Magnitude Ventures Group, Cure Ventures — 7 tracked in total.
- Tasca Therapeutics has filed 1 Form D with the SEC, most recently Nov 2024 ($24.1M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Tasca Therapeutics
Funding rounds
1 roundsAbout Tasca Therapeutics
Operator of a biotechnology company intended to develop small molecule drugs for hard-to-treat oncology indications. The company develops a pipeline of molecule therapeutics across multiple oncology indications, post-translational modification, and metabolic synergy to expand and effectively target the druggable proteome, enabling doctors to have molecule drugs for hard-to-treat oncology indications.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Website
- tascatx.com/
- Ownership
- Privately Held (backing)
Tasca Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tasca Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tasca Therapeutics in its N-PORT filings yet. We sweep new filings monthly.